Of the ~4,400 Escherichia coli (E. coli) open reading frames, roughly a third have not had their encoded protein functions experimentally verified. This collection of genes creates a significant black box in our understanding of fundamental cellular physiology, especially when considering those genes of unknown function that are essential for viability. Much of what is known about gene function has followed from studies in bacteria where there are suites of powerful tools available that have been refined in model systems such as E. coli. Despite astounding advances in DNA sequencing and synthesis technologies, there is a remaining fundamental question that has piqued the interest of hundreds of investigators: what are the minimal requirements for life? The predominant approaches to answering this question have been to either computationally compare genomes and identify conserved core genes, or to randomly disrupt the genomes using transposons and deduce which genes do not tolerate interruption. These combined strategies form the cornerstone of our understanding of what comprises an essential genome.
Technical Details
This invention focuses on a new method of testing the function and essentialness of certain proteins. By bonding certain peptide tags to pre-selected proteins, the processive protease within the cell targets and degrades the protein of interest. Degradation can be induced by activating the proteolytic activity, either by induction of the protease, induction of an adapter for the protease or by addition of the protease to mixtures, allowing for the creation of novel cell physiologies. Cells lacking a putative drug target can be generated for comparative studies or for control experiments. Additionally, cell extracts or macromolecular assemblies can be generated that lack a specific component even if that component is necessary for the formation of the original complex.
Partnering Opportunity
The research team is looking for partners to develop the technology further for commercialization.
Cellular depletion of biomolecular targets
| Patent Number | US9243280 |
| Patent Status | Issued |
| Issue Date | - |
Cellular depletion of biomolecular targets
| Patent Number | US9243280 |
| Patent Status | Issued |
| Issue Date | January 26, 2016 |
CELLULAR DEPLETION OF BIOMOLECULAR TARGETS
| Patent Number | US20120214170A1 |
| Patent Status | Application |
| Issue Date | - |